Danaher Reports Fourth Quarter and Full Year 2024 Results

Core Insights - Danaher Corporation reported strong fourth quarter and full year results for 2024, with core revenue exceeding expectations across all segments [2][9] - The company is positioned for higher long-term growth, expanded margins, and stronger cash flow due to its focused transformation in life sciences and diagnostics [2][3] Key Fourth Quarter 2024 Results - Net earnings were $1.1 billion, or$1.49 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $2.14 [9] - Revenues increased by 2.0$6.5 billion, while non-GAAP core revenue rose by 1.0% [9] - Operating cash flow was $2.0 billion, and non-GAAP free cash flow was$1.5 billion [9] Key Full Year 2024 Results - Net earnings totaled $3.9 billion, or$5.29 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $7.48 [9] - Revenues were flat year-over-year at$23.9 billion, with non-GAAP core revenue decreasing by 1.5% [9] - Operating cash flow reached $6.7 billion, and non-GAAP free cash flow was$5.3 billion [9] First Quarter and Full Year 2025 Outlook - For Q1 2025, the company anticipates a low-single-digit decline in non-GAAP core revenue year-over-year [3] - For the full year 2025, a projected increase of approximately 3% in non-GAAP core revenue is expected [3] Segment Performance - Total sales growth for the fourth quarter was 2.0%, with biotechnology segment growth at 6.5%, life sciences at 5.5%, and diagnostics declining by 3.0% [19] - For the full year, total sales growth was flat, with biotechnology down 6.0%, life sciences up 2.5%, and diagnostics up 2.0% [21] Cash Flow and Financial Position - Total cash provided by operating activities for Q4 2024 was $2.0 billion, a 27.0$1.5 billion, a 29.5% increase from the previous year [24] Balance Sheet Highlights - As of December 31, 2024, total assets were $77.5 billion, down from$84.5 billion in 2023 [31] - Current liabilities decreased to $6.8 billion from$8.3 billion in the previous year [31] - Stockholders' equity was $49.5 billion, down from$53.5 billion in 2023 [31]